SE7514589L - Aminosyrapreparat for patienter med leversjukdom och sett att anvenda dessa preparat - Google Patents

Aminosyrapreparat for patienter med leversjukdom och sett att anvenda dessa preparat

Info

Publication number
SE7514589L
SE7514589L SE7514589A SE7514589A SE7514589L SE 7514589 L SE7514589 L SE 7514589L SE 7514589 A SE7514589 A SE 7514589A SE 7514589 A SE7514589 A SE 7514589A SE 7514589 L SE7514589 L SE 7514589L
Authority
SE
Sweden
Prior art keywords
patients
preparation
amino acid
way
acid preparations
Prior art date
Application number
SE7514589A
Other languages
English (en)
Other versions
SE425715B (sv
Inventor
J E Fischer
N N Yoshimura
T L Westman
F H Deindoerfer
Original Assignee
Massachusetts Gen Hospital
American Hospital Supply Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24181564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE7514589(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Gen Hospital, American Hospital Supply Corp filed Critical Massachusetts Gen Hospital
Publication of SE7514589L publication Critical patent/SE7514589L/sv
Publication of SE425715B publication Critical patent/SE425715B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
SE7514589A 1975-02-03 1975-12-23 Forfarande for framstellning av ett aminosyrapreparat, avsett for administration till humanpatienter med leversjukdom SE425715B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/546,689 US3950529A (en) 1975-02-03 1975-02-03 Amino acid formulations for patients with liver disease and method of using same

Publications (2)

Publication Number Publication Date
SE7514589L true SE7514589L (sv) 1976-08-04
SE425715B SE425715B (sv) 1982-11-01

Family

ID=24181564

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7514589A SE425715B (sv) 1975-02-03 1975-12-23 Forfarande for framstellning av ett aminosyrapreparat, avsett for administration till humanpatienter med leversjukdom

Country Status (16)

Country Link
US (1) US3950529A (sv)
JP (1) JPS51118839A (sv)
BE (1) BE838231A (sv)
CA (1) CA1050890A (sv)
DE (1) DE2556100A1 (sv)
DK (1) DK579875A (sv)
FR (1) FR2299023A1 (sv)
GB (1) GB1507951A (sv)
IL (1) IL48621A (sv)
IN (1) IN143663B (sv)
IT (1) IT1067502B (sv)
NL (1) NL169030C (sv)
NZ (1) NZ179655A (sv)
PH (1) PH11557A (sv)
SE (1) SE425715B (sv)
ZA (1) ZA7654B (sv)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112085A (en) * 1974-10-28 1978-09-05 Morelle Jean V Metallic compositions
US4053589A (en) * 1975-11-24 1977-10-11 Control Drug Inc. Method of treating nutritional deficiency during cardiac cachexia, diabetes, hypoglycemia, gastroenterology, lipid, cell glycogen and keratin-related skin conditions and alcoholism
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
US4042688A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of providing high-protein nutrition by the oral administration of a predigested protein composition
DE2636828A1 (de) * 1976-08-16 1978-02-23 Fresenius Chem Pharm Ind L-amonosaeurengemische fuer die behandlung von leberinsuffizienz sowie die herstellung derartiger gemische
DE2642768A1 (de) * 1976-09-23 1978-03-30 Fresenius Chem Pharm Ind Essentielle und nicht essentielle l-aminosaeuren enthaltendes gemisch zur behandlung von leberinsuffizienz
DE2750159C3 (de) * 1977-11-09 1980-05-22 Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4210637A (en) * 1978-07-31 1980-07-01 Massachusetts Institute Of Technology Composition and method for suppressing appetite for calories as carbohydrates
JPS5536457A (en) * 1978-09-08 1980-03-14 Ajinomoto Co Inc Amino acid infusion
IT1100677B (it) * 1978-11-03 1985-09-28 Boehringer Biochemia Srl Formazione farmaceutica iniettabile a base di amminoacidi
JPS568312A (en) * 1979-07-03 1981-01-28 Otsuka Pharmaceut Factory Inc Amino acid pharmaceutical preparation
JPS5668374A (en) * 1979-11-08 1981-06-09 Jun Sawada Food composition for hepatic insufficiency
DE2946563A1 (de) * 1979-11-17 1981-05-21 B. Braun Melsungen Ag, 3508 Melsungen Aminosaeureloesung zur parenteralen infusion
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US4438144A (en) 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US4574085A (en) * 1981-05-15 1986-03-04 Baxter Travenol Laboratories, Inc. Method for using dialysis solution containing glycerol
US4898879A (en) * 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
CA1184499A (en) * 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
JPS5835685U (ja) * 1981-08-31 1983-03-08 三菱電機株式会社 電動圧縮機の支持装置
JPS5856177U (ja) * 1981-10-13 1983-04-16 ダイキン工業株式会社 圧縮機の取付装置
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
JPS5916817A (ja) * 1982-07-16 1984-01-28 Eisai Co Ltd アミノ酸輸液
FR2556594B1 (fr) * 1983-12-20 1988-09-09 Synthelabo Solutions d'acides amines
JPS6150917A (ja) * 1984-08-20 1986-03-13 Ajinomoto Co Inc 抗アルコ−ル性肝障害組成物
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
US5039704A (en) * 1985-09-12 1991-08-13 Brigham And Women's Hospital Method of treating catabolic dysfunction
US5607975A (en) * 1985-09-12 1997-03-04 Brigham And Women's Hospital Method of treating catabolic, gut-associated pathological processes and impaired host defenses
US4857555A (en) * 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US5397803A (en) * 1985-09-12 1995-03-14 Brigham And Women's Hospital Use of glutamine to reduce rate of pathogenic microorganism infection
US5763485A (en) * 1985-09-12 1998-06-09 Brigham And Women's Hospital Method of treating catabolic, gut-associated pathological processes and impaired host defenses
JPH0667831B2 (ja) * 1986-01-13 1994-08-31 森永乳業株式会社 肝物質合成機能障害改善用のアミノ酸組成物
US4859452A (en) * 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US5162373A (en) * 1986-01-17 1992-11-10 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
JP2599593B2 (ja) * 1986-06-26 1997-04-09 株式会社 大塚製薬工場 腎不全用アミノ酸輸液
JPS6314728A (ja) * 1986-07-03 1988-01-21 Zeria Shinyaku Kogyo Kk 肝障害の予防、治療剤
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US5248688A (en) * 1986-09-10 1993-09-28 Dudrick Medical Research Fund I, Ltd. Method and substrate composition for treating atherosclerosis
GB2199243A (en) * 1986-09-17 1988-07-06 Natural Vitality Ltd Pharmaceutical compositions comprising ornithine and arginine
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
US5639731A (en) * 1987-05-22 1997-06-17 Pripps Bryggerier Ab Amino acids for the preparation of a beverage
AU1942488A (en) * 1987-05-22 1988-12-21 Ab Pripps Bryggerier Use of amino acids for the preparation of a beverage
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
JPH0277550A (ja) * 1988-09-12 1990-03-16 Furukawa Alum Co Ltd 成形加工用快削アルミニウム合金とその製造方法
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
DE4134723C1 (sv) * 1991-10-21 1993-02-11 Pfrimmer Kabi Gmbh & Co Kg, 8520 Erlangen, De
US5266685A (en) * 1992-05-05 1993-11-30 Grain Processing Corporation Non-bitter protein hydrolyzates
JPH06109286A (ja) * 1992-09-28 1994-04-19 Daikin Ind Ltd 圧縮機の取付構造
US5292722A (en) * 1992-11-06 1994-03-08 Brigham And Women's Hospital Intravenous solution that diminishes body protein loss
AU6232794A (en) * 1993-01-29 1994-08-15 Brigham And Women's Hospital The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US20040022827A1 (en) * 1997-09-30 2004-02-05 Chugai Seiyaku Kabusiki Kaisha Remedy for hepatopathy
FR2800243B1 (fr) * 1999-11-02 2002-01-18 Royal Canin Sa Composition alimentaire ou veterinaire pour carnivore domestique contenant de la tyrosine libre pour prevenir les anomalies de pigmentation du pelage
US20010014442A1 (en) * 2000-02-09 2001-08-16 Morris James G. Essential constituent and method of use for maintaining hair coloration or reversing hair discoloration
WO2002060431A1 (fr) * 2001-01-30 2002-08-08 Ajinomoto Co., Inc. Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires
US20040192751A1 (en) * 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
US20020193342A1 (en) * 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
WO2005082159A1 (ja) * 2004-02-27 2005-09-09 Nosan Corporation 食物アレルギー反応低減ペットフード
EP2319581B1 (en) * 2004-11-26 2015-02-25 UCL Business PLC Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2006061992A1 (ja) * 2004-12-10 2006-06-15 Ajinomoto Co., Inc. 肝疾患予防・治療用組成物
CA2601895C (en) 2005-03-21 2014-06-10 Abbott Laboratories Amino acid composition for improving glucose tolerance
KR20220067001A (ko) 2009-04-03 2022-05-24 오세라 테라퓨틱스, 아이엔씨. Ｌ-오르니틴 페닐 아세테이트, 및 이의 제조방법
ES2728948T3 (es) 2009-06-08 2019-10-29 Ucl Business Plc Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
EP2986250A4 (en) * 2013-04-16 2017-03-22 Molecular Systems Ltd. Laser assisted periodontium and osseus regeneration protocol
AU2015353703B2 (en) 2014-11-24 2021-04-01 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
US11654293B2 (en) 2016-11-10 2023-05-23 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
WO2018089954A1 (en) 2016-11-10 2018-05-17 BioRegentech Laser assisted wound healing protocol and system
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2666013A (en) * 1950-08-25 1954-01-12 Jr Edgar A Ferguson Pruritus therapy
US3256095A (en) * 1962-10-17 1966-06-14 Union Carbide Corp Nutritional utilization of amino acid amides and acid salts thereof
DE1667887C2 (de) * 1968-02-09 1978-09-28 Knauff, Hans Georg, Prof. Dr., 3551 Dagobertshausen Aminosäurelösung zur parenteralen Infusion
GB1256162A (en) * 1968-08-16 1971-12-08 Braun Fa B Improvements in and relating to liquid products for intravenous administration
US3697287A (en) * 1969-01-28 1972-10-10 Morton Norwich Products Inc Amino acid food composition
US3764703A (en) * 1969-11-07 1973-10-09 Astra Ab Amino acid mixture for use in treatment of uremic conditions
US3773930A (en) * 1971-03-23 1973-11-20 Johnson & Johnson Amino acid composition
US3832465A (en) * 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
GB1442154A (en) * 1973-04-30 1976-07-07 Walser M Composition for promotion of protein synthesis and suppression of urea formation in the body

Also Published As

Publication number Publication date
NL7515199A (nl) 1976-08-05
DE2556100C2 (sv) 1987-06-19
NL169030B (nl) 1982-01-04
PH11557A (en) 1978-03-31
CA1050890A (en) 1979-03-20
IN143663B (sv) 1978-01-14
SE425715B (sv) 1982-11-01
GB1507951A (en) 1978-04-19
AU1024076A (en) 1977-07-21
ZA7654B (en) 1977-01-26
BE838231A (fr) 1976-05-28
JPS5627493B2 (sv) 1981-06-25
IL48621A (en) 1978-09-29
JPS51118839A (en) 1976-10-19
FR2299023B1 (sv) 1979-09-28
NL169030C (nl) 1982-06-01
NZ179655A (en) 1978-03-06
DK579875A (da) 1976-08-04
IL48621A0 (en) 1976-02-29
DE2556100A1 (de) 1976-08-05
US3950529A (en) 1976-04-13
IT1067502B (it) 1985-03-16
FR2299023A1 (fr) 1976-08-27

Similar Documents

Publication Publication Date Title
SE7514589L (sv) Aminosyrapreparat for patienter med leversjukdom och sett att anvenda dessa preparat
NO781079L (no) Preparat med regulert medikamentfrigjoering
NO770465L (no) Fremgangsm}te for fremstilling av fysiologisk aktive karboksyalkylacyl-aminosyrer.
FI801876A (fi) Farmaceutiska preparat
ES491183A0 (es) Procedimiento para la preparacion de acidos 3-cefem-4-carbo-xilicos sustituidos en la posicion 7
NO784211L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO143219C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
DK371277A (da) Fremgangsmaade til fremstilling af farmaceutiske doseringsformer med vedvarende virkning
NL7613208A (nl) Werkwijze ter bereiding van plantenziekte be- strijdingsmiddelen alsmede preparaten onder toepassing hiervan.
SE7602317L (sv) 1,4-dihydropyridinkarbonsyraalkylestrar till anvendning som lekemedel och sett att framstella desamma
SE7607825L (sv) 2,4-diklor-4'-bensoylureido-difenyletrar till anvendning som insekticider och sett for deras framstellning
NO146394C (no) Analogifremgangsmaate til fremstilling av 1,2-difenyl-3-(imidazol-1-yl)-propan-2-oler med terapeutisk virkning
NO773038L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive fenyletylaminer
NO773327L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrazolopyridiner
IT1164076B (it) Composti farmaceutici ad azione antiulcera e procedimento per la loro preparazione
FR2348704A1 (fr) Procede de preparation d'un vaccin contre le virus de la rhinopneumonie equine et vaccin ainsi obtenu
NO781878L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner.
FI773568A (fi) Farmaceutiska preparat med laongtidsverkan
SE7710637L (sv) Alkoxisubstituerade pyrimidinyltionofosfonsyraestrar till anvendning som insekticider och akaricider och sett att framstella foreningarna
SE7806244L (sv) Foreningar i pregnanserien med syrefunktion i 19-stellning, forfarande for framstellning derav och farmaceutiska preparat innehallande dessa foreningar
NO773344L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive pyridobenzodiazepinoner
NO142525C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive isotiourinstoff-forbindelser
SE7609227L (sv) Vinyltionofosforsyraestrar till anvendning som insekticider och akaricider och sett for deras framstellning
SE7608760L (sv) (tiono) (thiol)pyridazinonalkanfosfonsyraestrar till anvendning som insekticider och akaricider och sett for deras frastellning
IT8019070A0 (it) Oligopeptidi trifluorometilati, loro procedimento di preparazione eloro applicazione terapeutica